MedTrace Logo

Effect of Intraarticular Injection of Tenoxicam and Hyaluronic Acid Versus Platelet-Rich Plasma and Hyaluronic Acid in Temporomandibular Joint Internal Derangement

NCT06572904 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-08-27

No results posted yet for this study

Summary

To compare the effect of intraarticular injection of Tenoxicam and Hyaluronic acid Versus Platelet-rich plasma and Hyaluronic acid in the management of patients with TMJ internal derangement with reduction.

Conditions

  • Temporomandibular Joint Internal Derangement

Interventions

DRUG

Tenoxicam Injectable Product

(EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)

DRUG

Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly

\* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Sally Awad, Prof · Professor of Oral and Maxillofacial Surgery Faculty of Dentistry - Mansoura University

  • Amira Attia, Dr · Lecturer of Oral and Maxillofacial Surgery Faculty of Dentistry- Mansoura University

  • Manar Mansour, Dr · Lecturer of Diagnostic and Interventional Radiology Faculty of Medicine- Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-20
Primary Completion
2024-10-20
Completion
2024-11-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06572904 on ClinicalTrials.gov